## Sunlenca (Lenacapavir sodium tablets) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUN	MBER:			
MALE FEMALE HEIG	BER, YOU WILL NEED TO SUBMIT A PHI DISCLO NOPP	SURE AUTHORIZATION FORM WITH THIS REQU	JEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPR AUTHORIZED REPRESENTATIV				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL D	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
□ NEW THERAPY     □ RENEWAL     IF       DURATION OF THERAPY (SPECIFIC DATES):		IF RENEWAL: DATE THERAPY	INITIATED:	
	- ,			

Continued on next page.



## Sunlenca (Lenacapavir sodium tablets) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	ME: MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below)	NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ HIV-1 infection			
□ Other diagnosis:	ICD-10:		
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A	
Clinical Information:			
Will Sunlenca be used as part of a clir	nical trial? 🗆 Yes 🗆 No		
Is the patient heavily treatment expe	rienced with multidrug resistant HIV-1 i	nfection? □ Yes □ No	
•	esistance to > 2 antiretroviral (ARV) med Online Yes   Online No Please submit documentat		nain
Does patient have documented resis documentation.	tance to 2 nucleoside reverse-transcript	ase [NRTIs]? □ Yes □ No <i>Please sub</i>	mit
Does patient have documented resis No <i>Please submit documentation</i> .	tance to 2 nonnucleoside reverse-trans	criptase inhibitors [NNRTIs]?   Yes	
Does patient have documented resist	tance to 2 protease inhibitors [PIs]? $\Box$ Yo	es 🗆 No Please submit documentation	on.
Does patient have documented resist submit documentation.	tance to 2 integrase strand-transfer inhi	bitors [INSTI])? □ Yes □ No <i>Please</i>	
Does the patient have at least 2 fully combined?   Yes  No Please submit	active ARV drugs remaining from the 4 tocumentation.	main classes that can be effectively	
Does patient have an HIV-1 RNA leve	l of <u>&gt;</u> 400 copies per milliliter?   Yes	Io Please submit documentation.	
Does the patient have a history of tre Please submit documentation.	eatment failure or known or suspected r	esistance to lenacapavir?   Yes   N	lo
Will the tablets be used for oral induc	ction with Sunlenca (lenacapavir)? 🗆 Yes	s □ No	
Will Sunlenca (lenacapavir) be used v submit documentation.	vith other antiretrovirals (optimized bac	kground regimen)? ☐ Yes ☐ No <i>Plea</i>	ise
Are there any other comments, diagraphysician feels is important to this re	noses, symptoms, medications tried or for the view?	ailed, and/or any other information	the



## Sunlenca (Lenacapavir sodium tablets) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

<b>Please note:</b> Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification: Date:
<b>CONFIDENTIALITY NOTICE:</b> The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

